← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Combinations of monoclonal antibodies and antibody drug conjugates
nivolumab and relatlimab
L01FY02
Forms & Strengths
- Injection: 240mg/100mg per 10mL vial
- Fixed-dose combination of nivolumab and relatlimab
Adult Dosing
- 420mg nivolumab and 170mg relatlimab every 4 weeks
- Dosage adjustment not required for renal or hepatic impairment
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
- Use in pediatric patients is not recommended
Indications
- Unresectable or metastatic melanoma
- Treatment of adult patients with advanced melanoma
Mechanism of Action
- Nivolumab: PD-1 receptor antagonist
- Relatlimab: LAG-3 receptor antagonist
- Dual immune checkpoint inhibition enhances T-cell activation and proliferation
Contraindications
- Hypersensitivity to nivolumab, relatlimab, or any component of the product
- Immune-mediated adverse reactions, including immune-related pneumonitis and colitis
Adverse Reactions
- Fatigue, musculoskeletal pain, rash, and pruritus
- Immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, and endocrinopathies
- Infusion-related reactions, including anaphylaxis
Drug Interactions
- Concomitant use with immunosuppressive agents may decrease efficacy
- Concomitant use with vaccines may lead to decreased vaccine efficacy
Curated Content: Needs Vetting Before Put to Clinical Use